Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Alkermes Spiked Today

By Brian Feroldi - Feb 14, 2018 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Expectation-topping results mixed with upbeat guidance put Wall Street in a good mood.

What happened

In response to reporting fourth-quarter results and sharing guidance for 2018, shares of Alkermes (ALKS 2.48%), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, rose as much as 10% on Wednesday. Shares settled down in afternoon trading but were still up 7% as of 2:30 p.m. EST.

So what

Here's a review of the headline numbers from the quarter:

  • Revenue jumped 29% to $275 million thanks to broad strength in product sales and the company's recently announced deal with Biogen (BIIB 3.28%). That sailed past the $253 million in revenue that Wall Street had projected.
  • Non-GAAP net income more than doubled to $50.3 million, or $0.33 per share. That also compared favorably to the $0.23 that analysts had modeled.
A person in a suit giving thumbs up as money falls in the background.

Image source: Getty Images.

Looking beyond the financials, Alkermes also provided investors with a review of its recent business developments:

  • ALKS 5461, a hopeful treatment for depression that has already achieved Fast Track status, was successfully submitted to the FDA for review.
  • Alkermes' agreement with Biogen could allow the company to earn up to $200 million in milestone payments plus royalties on any product sales should everything go according to plan.
  • Aripiprazole Lauroxil NanoCrystal Dispersion, which is a compound that helps patients get started with Alkermes' schizophrenia drug Aristada, has been submitted for regulatory review.

Turning to 2018, here's the guidance that management is offering investors:

  • Revenue is expected to land between $975 million and $1.025 billion. The midpoint of this range is slightly ahead of what Wall Street was expecting.
  • Non-GAAP net loss is expected to be between $5 million to $35 million, or $0.03 to $0.23 per share. This is behind the $0.44 in EPS that analysts were projecting. 

Given the strong fourth-quarter results, it isn't hard to figure out why shareholders are having a good day.

Now what

Alkermes has set itself up to have an action packed 2018. All of the company's products look poised for continued growth and go/no-go decisions are expected on both ALKS 5461 and Aripiprazole Lauroxil NanoCrystal Dispersion. Meanwhile, Biogen looks poised to submit BIIB098 for regulatory review -- which should trigger a $50 million milestone payment -- and investors should also get a look at phase 2 results for a schizophrenia product candidate called ALKS 3831.

Investors have reason to believe CFO James Frates when he says that 2018 should be a "transformative year" for Alkermes. That's why Alkermes stock is capable of still moving higher, even after accounting for Wednesday's big jump.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$210.63 (3.28%) $6.69
Alkermes plc Stock Quote
Alkermes plc
$30.53 (2.48%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.